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Aims: To study single dose pharmacokinetics of lamivudine (3TC) in healthy subjects.  
Methods: Twelve healthy subjects were administered 3TC (150 mg) followed by timed blood and urine 
collections up to 24 hours. Pharmacokinetic variables and percent dose of 3TC in urine were 
calculated.  
Results: Plasma exposure and percent dose of 3TC in urine were highly correlated (p < 0.001; r = 
0.96). 3TC concentration at 24 hours was undetectable in all study subjects.  
Conclusions: Timed urine measurements could be used to study bioavailabilty of 3TC. Plasma 3TC 
measurements could be used to monitor adherence among HIV-infected patients on antiretroviral 
treatment.  
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Introduction 
 
Lamivudine (3TC) forms an important 
component of highly active antiretroviral therapy 
(HAART) that is used to treat HIV-infected 
individuals in India.  It is well tolerated and can 
be administered as either 150mg bi-daily or 300 
mg once-daily along with other antiretroviral 
drugs.  Lamivudine is present in all fixed dose 
combination (FDC) pills, has a short elimination 
half-life, and hence estimation of the drug in spot 
urine could be useful in monitoring patient 
adherence to antiretroviral treatment (1).  Earlier 
studies have shown that 3TC exhibits similar 
pharmacokinetic profiles in healthy volunteers, 
asymptomatic HIV-infected individuals and 
patients with AIDS (2, 3).  The primary 
pharmacokinetic parameters of 3TC in Indian 
subjects have been shown to be comparable to 
those previously reported in other populations 
(4).  We undertook a single dose 
pharmacokinetic study of 150 mg 3TC in healthy 
subjects with the aim of correlating plasma 
exposure of 3TC with that of percent dose of 
3TC excreted in urine over a particular period of 
time, and also to assess the feasibility of 
monitoring patient adherence to antiretroviral 
treatment using a trough plasma concentration of 
3TC. 
 
Methods 
 
Subjects: Healthy adult males meeting the 
following inclusion criteria were recruited to the 
study. (i) aged 20 to 60 years (ii) body weight > 
45 kg (iii) not suffering from any illness [blood 
chemistry (random blood glucose, creatinine, 
transaminases) and hematology (hemoglobin, 
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total & differential counts) parameters within 
normal limits] (iv) not taking concurrent 
medications at the time of the study and (v) 
willing to give informed written consent. Smokers 
and chronic alcoholics were not included into the 
study.   
 
Conduct of study: The study was carried out at 
the Pharmacology Ward in Madras Medical 
College, Chennai, India, and commenced after 
obtaining clearance from the Institutional Ethics 
Committees of Tuberculosis Research Centre, 
Chennai and Madras Medical College, Chennai. 
Eligible study participants were admitted to the 
ward a day prior to the study.  Informed written 
consent was obtained from all the volunteers 
before start of the study. 
 
On the day of the study, they were instructed to 
empty their bladder.  A sample of blood (3ml) 
was collected in a heparinised vacutainer (0 
hour), after a 12-hour fast. They were 
administered 3TC (150mg) under supervision 
with 200ml water.  Blood samples were collected 
at 1, 2, 4, 6, 8, 12 and 24 hours after drug 
administration.  They were instructed to make 
complete urine collections excreted up to 24 
hours after drug administration. Breakfast, lunch 
and dinner were provided uniformly to all the 
study participants. 
 
The blood samples were centrifuged immediately 
and plasma stored at -20ºC until estimation of 
3TC was undertaken. The total volume of urine 
was measured and aliquots stored at -20° C until 
analysis of 3TC.  
 
Estimation of plasma and urine lamivudine: 
Lamivudine concentrations in plasma and urine 
were estimated by HPLC (Shimadzu 
Corporation, Kyoto, Japan) according to 
validated methods described earlier (5, 1). 
 
Pharmacokinetic analysis: Certain 
pharmacokinetic variables such as peak 
concentration, time to attain peak concentration, 
exposure (0 to 24 hours & 0 to infinity), 
clearance and half-life were calculated 
employing a non - compartmental model 
following first-order kinetics using WinNonlin 
software (Version 5.1) (Pharsight Corporation, 
Mountain View, CA, USA).  
 
The percent dose of 3TC excreted in urine 
collected between 0 to 24 hours was calculated  
Statistical Evaluation: Analysis of data was 
performed using SPSS (version 13) package. 
Pearson’s correlation test was used to evaluate 
correlation between plasma exposure of 3TC 
with that of percent dose of 3TC excreted in 
urine over a 24-hour period.  
 
Results  
 
The pharmacokinetic study of 3TC was 
conducted in 12 healthy adult Indian men whose 
age, body weight and height ranged from 19-25 
years, 54-71 kg and 162-175.5 cm respectively. 
The peak concentration of 3TC was achieved at 
about one hour, suggesting rapid and almost 
complete absorption. Lamivudine was 
undetectable in plasma at 24 hours in all the 12 
study subjects. The major pharmacokinetic 
variables and percent dose of 3TC in urine are 
given in Table 1. The correlation between 
plasma exposure (0 to infinity) and percent dose 
of 3TC excreted in urine between 0 to 24 hours 
was highly significant (p < 0.001; r = 0.96). 
 
Table 1 Plasma & urine estimates of lamivudine 
in 12 healthy subjects 
 
Parameters Mean + SD 
Peak concentration (µg/ml) 1.56 + 0.51 
Time to attain peak concentration (h) 1.25 + 0.45 
Exposure (0-24h) (µg/ml.h) 6.56 + 2.52 
Exposure (0-infinity) (µg/ml.h) 6.98 + 2.63 
Clearance (L/h) 25.48  + 12.66 
Half-life (h) 2.38 + 0.69 
% dose in urine (0-24 h) 77.05 + 14.22 
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Discussion 
 
A high degree of correlation usually exists 
between plasma and urine estimates of those 
drugs whose primary route of elimination is 
through the kidneys. Although the route of 
elimination of 3TC is mainly renal, knowledge 
about urinary excretion of 3TC and its correlation 
with plasma concentrations is not available in the 
literature. This single dose pharmacokinetic 
study in healthy volunteers has demonstrated 
that urine 3TC excreted over a period of 24 
hours was highly correlated with plasma 
exposure, which suggests that urine 3TC 
estimations can be used to infer bioavailability of 
the drug. This finding is particularly important 
and could be useful in situations where 
bioequivalence studies of 3TC are performed. 
Thus invasive blood collections can be replaced 
by simple, non-invasive urine collections. The 
study has also demonstrated the usefulness of 
plasma 3TC in predicting antiretroviral treatment 
adherence. At a dose of 150mg, 3TC was 
measurable in blood collected at 12 hours, but 
could not be detected at 24 hours. This suggests 
that if 3TC is not measured in blood collected at 
a particular time point, the patient has not taken 
the drug in the last 12 hours or longer. Thus, 
information on one or more missed doses can be 
obtained. Since 3TC is present in all FDC pills 
manufactured in India and other countries, 
trough plasma 3TC estimation can be used as a 
marker for predicting antiretroviral treatment 
adherence of patients. A similar approach has 
been reported by Liechty et al (6), who reported 
that abnormally low, untimed antiretroviral drug 
levels in blood could identify individuals with very 
low adherence at high risk of HIV disease 
progression and death. Measurement of 3TC in 
urine and indinavir in saliva has been reported to 
be useful in monitoring patient compliance to 
treatment (1, 7). Plasma 3TC estimation could 
serve as yet another means to monitor 
antiretroviral treatment adherence.  
 
The pharmacokinetic profile of 3TC obtained in 
healthy Indian subjects is similar to that reported 
by Narang et al. (4). However, the elimination 
half-life was lower than that reported in White 
and Hispanic subjects (2, 3). Since plasma 3TC 
concentrations are of limited value in evaluating 
efficacy or toxicity, it may be of interest to 
establish the pharmacokinetic profile of the 
parent drug and its intracellular metabolite in 
different populations.  
 
A notable limitation of this study was that it was a 
single dose pharmacokinetic study done in 
healthy subjects. It is important to study the 
pharmacokinetics of 3TC in HIV-infected persons 
who have been receiving the drug for a long 
period of time. In summary, the study has shown 
a good correlation between plasma and urine 
concentrations of 3TC, suggesting that timed 
urine measurements could be used to study the 
bioavailabilty of 3TC. Plasma 3TC 
measurements could serve as a useful tool to 
predict adherence to antiretroviral treatment. 
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